Updated study results of novel FAK/ALK/ROS1 inhibitor APG-2449 in patients (pts) with non-small-cell lung cancer (NSCLC) resistant to second-generation ALK inhibitors.,Journal of Clinical Oncology

当前位置： X-MOL 学术 › J. Clin. Oncol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Updated study results of novel FAK/ALK/ROS1 inhibitor APG-2449 in patients (pts) with non-small-cell lung cancer (NSCLC) resistant to second-generation ALK inhibitors.
Journal of Clinical Oncology ( IF 42.1 ) Pub Date : 2024-05-29 , DOI: 10.1200/jco.2024.42.16_suppl.3124
Yuxiang Ma ₁ , Hongyun Zhao ₁ , Jianhua Chen ₂ , Zhengbo Song ₃ , Yanqiu Zhao ₄ , Yubiao Guo ₅ , Gang Wu ₆ , Hua Yang ₂ , Xiaoqing Yu ₃ , Fangfang Gao ₇ , Ruiguang Zhang ₆ , Jian Fang ₈ , Xiaoyan Lin ₉ , GuangLin Liu ₁₀ , Chen Yang ₁₀ , Lichuang Men ₁₀ , Eric Liang ₁₁ , Dajun Yang ₁₂ , Li Zhang ₁ , Yifan Zhai ₁₃

Affiliation

Sun Yat-sen University Cancer Center, Guangzhou, China
Hunan Provincial Oncology Hospital, Changsha, China
Zhejiang Cancer Hospital, Hangzhou, China
The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China
The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China
Union Hospital Medical College, Huazhong University of Science and Technology, Wuhan, China
Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China
Peking University Cancer Hospital, Peking University, Beijing, China
Union Hospital, Fujian Medical University, Fuzhou, China
Ascentage Pharma (Suzhou) Co., Ltd., Suzhou, China
Ascentage Pharma Group Inc., Rockville, MD
Ascentage Pharma (Suzhou) Co., Ltd., Suzhou, China, Ascentage Pharma Group Inc., Rockville, MD, and State Key Laboratory of Oncology in South China Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China
Ascentage Pharma (Suzhou) Co., Ltd., Suzhou, China, and Ascentage Pharma Group Inc., Rockville, MD